Resensitization of β-adrenergic receptor (βAR) occurs by dephosphorylation of the internalized βAR by protein phosphatase 2A (PP2A) before being recycled back to plasma membrane (PM). Contrary to this classical paradigm, cardiac specific expression of inactive PI3Kγ (PI3Kγ inact ) leads to receptor resensitization at the plasma membrane as measured by adenylyl cyclase activity in mice chronically treated with the agonist. We hypothesized that PI3K activity inhibits PM receptor resensitization. Using cells stably expressing FLAG-β 1 AR alone (single) or along with PI3Kγ inact (double), we show that inhibition of PI3K activity results in novel PM receptor resensitization. Agonist activation of single stables showed significant receptor desensitization as measured by reduced cAMP generation (35.6 ± 4.6 pmol/mg protein). In contrast, double-or wortmannin (Wort, PI3K inhibitor) pre-treated single- stables showed marked generation of cAMP (87.4 ± 3.2 or 83.1 ± 5.7) showing β 1 AR resensitization. Agonist stimulation of metabolically labeled β 1 ARs pre-treated with inhibitors of internalization, sucrose and β-cyclodextrin resulted in accumulation of phosphorylated receptors at the PM, which was abolished with PI3Kγ inact suggesting dephosphorylation of β 1 ARs. Inhibition of PP2A by okadaic acid or Fostriecin resulted in complete loss of β 1 AR resensitization despite the presence of PI3Kγ inact showing that PI3K regulates PP2A activity at the β 1 AR complex. Pre-treatment of single stable cells with Wort resulted in significant increase in β 1 AR-associated phosphatase activity following dobutamine (Dob) treatment (Veh, 4131 ± 14; Dob, 3180 ± 111; Dob + Wort, 17123 ± 680 pmoles/mg protein). Consistently, similar results were obtained in vivo using single transgenic (FLAG-β 1 AR, Veh, 87 ± 12; Dob, 61.7 ± 8.3) and double transgenic (FLAG-β 1 AR and PI3Kγ inact , Veh, 93 ± 9; Dob, 118 ± 6) mice. In vivo metabolic labeling, co-immunoprecipitation and in vitro kinase assays showed that inhibitor of PP2A (I2PP2A) protein as a target of PI3K in regulating PP2A activity at the β 1 AR complex. Indeed, siRNA knock down of I2PP2A results in preservation of β 1 AR function by PM receptor resensitization demonstrating a novel role for PI3K in receptor resensitization. This research has received full or partial funding support from the American Heart Association, AHA Great Rivers Affiliate (Delaware, Kentucky, Ohio, Pennsylvania & West Virginia).